Ulrike Raap

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6976152/publications.pdf Version: 2024-02-01



HIDIKE RAAD

#	Article	IF	CITATIONS
1	Correlation of IL-31 serum levels with severity of atopic dermatitis. Journal of Allergy and Clinical Immunology, 2008, 122, 421-423.	2.9	272
2	Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology, 2012, 56, 1391-1400.	7.3	228
3	ILâ€31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. Pediatric Allergy and Immunology, 2012, 23, 285-288.	2.6	139
4	Histamine and T helper cytokine–driven epithelial barrier dysfunction in allergic rhinitis. Journal of Allergy and Clinical Immunology, 2018, 141, 951-963.e8.	2.9	139
5	Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2427-2436.	5.7	136
6	Human mast cells and basophils—How are they similar how are they different?. Immunological Reviews, 2018, 282, 8-34.	6.0	124
7	Brain-derived neurotrophic factor is increased in atopic dermatitis and modulates eosinophil functions compared with that seen in nonatopic subjects. Journal of Allergy and Clinical Immunology, 2005, 115, 1268-1275.	2.9	121
8	Investigation of contact allergy to dental metals in 206 patients. Contact Dermatitis, 2009, 60, 339-343.	1.4	113
9	H1â€antihistamineâ€refractory chronic spontaneous urticaria: it's worse than we thought – first results of the multicenter realâ€life <scp>AWARE</scp> study. Clinical and Experimental Allergy, 2017, 47, 684-692.	2.9	96
10	Human basophils are a source of ―and are differentially activated by ―ILâ€31. Clinical and Experimental Allergy, 2017, 47, 499-508.	2.9	95
11	Circulating levels of brainâ€derived neurotrophic factor correlate with disease severity in the intrinsic type of atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 1416-1418.	5.7	90
12	Increased levels of serum ILâ€31 in chronic spontaneous urticaria*. Experimental Dermatology, 2010, 19, 464-466.	2.9	75
13	Brachioradial pruritus as a result of cervical spine pathology: The results of a magnetic resonance tomography study. Journal of the American Academy of Dermatology, 2011, 65, 756-762.	1.2	71
14	IL-31 Induces Chemotaxis, Calcium Mobilization, Release of Reactive Oxygen Species, and CCL26 in Eosinophils, Which Are Capable to Release IL-31. Journal of Investigative Dermatology, 2015, 135, 1908-1911.	0.7	71
15	Pathophysiology of itch and new treatments. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 420-427.	2.3	66
16	ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. British Journal of Dermatology, 2016, 174, 892-894.	1.5	61
17	Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. Journal of Allergy and Clinical Immunology, 2013, 132, 232-235.e4.	2.9	60
18	The role of neurotrophins in the pathophysiology of allergic rhinitis. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 8-13.	2.3	56

Ulrike Raap

#	Article	IF	CITATIONS
19	S2k‣eitlinie zur Diagnostik und Therapie des chronischen Pruritus – Update – Kurzversion. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-873.	0.8	56
20	Eosinophils are a Major Source of Interleukin-31 in Bullous Pemphigoid. Acta Dermato-Venereologica, 2018, 98, 766-771.	1.3	56
21	Mobile Augmented Reality as a Feature for Self-Oriented, Blended Learning in Medicine: Randomized Controlled Trial. JMIR MHealth and UHealth, 2017, 5, e139.	3.7	49
22	Antihistamineâ€resistant chronic spontaneous urticaria: 1â€year data from the AWARE study. Clinical and Experimental Allergy, 2019, 49, 655-662.	2.9	45
23	Differential upâ€regulation of neurotrophin receptors and functional activity of neurotrophins on peripheral blood eosinophils of patients with allergic rhinitis, atopic dermatitis and nonatopic subjects. Clinical and Experimental Allergy, 2008, 38, 1493-1498.	2.9	43
24	European <scp>EADV</scp> network on assessment of severity and burden of Pruritus (PruNet): first meeting on outcome tools. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1144-1147.	2.4	41
25	Neuronal branching of sensory neurons is associated with BDNFâ€positive eosinophils in atopic dermatitis. Clinical and Experimental Allergy, 2020, 50, 577-584.	2.9	40
26	Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). Acta Dermato-Venereologica, 2019, 99, 379-385.	1.3	40
27	Substance P activates human eosinophils. Experimental Dermatology, 2015, 24, 557-559.	2.9	38
28	Interleukin-31 Signaling Bridges the Gap Between Immune Cells, the Nervous System and Epithelial Tissues. Frontiers in Medicine, 2021, 8, 639097.	2.6	37
29	High mobility group box 1 (HMGB1) acts as an "alarmin―to promote acute myeloid leukaemia progression. Oncolmmunology, 2018, 7, e1438109.	4.6	34
30	Neurological disorders are associated with bullous pemphigoid. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 925-929.	2.4	32
31	Human basophil chemotaxis and activation are regulated via the histamine H4 receptor. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1264-1273.	5.7	28
32	A new paradigm of eosinophil granulocytes: neuroimmune interactions. Experimental Dermatology, 2008, 17, 731-738.	2.9	27
33	S2k Guidelines for the diagnosis and treatment of chronic pruritus – update – short version. JDDG - Journal of the German Society of Dermatology, 2017, 15, 860-872.	0.8	23
34	Increased Activity and Apoptosis of Eosinophils in Blister Fluids, Skin and Peripheral Blood of Patients with Bullous Pemphigoid. Acta Dermato-Venereologica, 2017, 97, 464-471.	1.3	23
35	Lupus erythematosus tumidus: clinical perspectives. Clinical, Cosmetic and Investigational Dermatology, 2019, Volume 12, 707-719.	1.8	22
36	IgE autoantibodies in serum and skin of nonâ€bullous and bullous pemphigoid patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 973-980.	2.4	22

ULRIKE RAAP

#	Article	IF	CITATIONS
37	Practical recommendations for the allergological risk assessment of the COVID-19 vaccination – a harmonized statement of allergy centers in Germany. Allergologie Select, 2021, 5, 72-76.	3.1	22
38	Childhood atopic dermatitis—Brainâ€derived neurotrophic factor correlates with serum eosinophil cationic protein and disease severity. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 1062-1065.	5.7	21
39	Pirfenidoneâ€induced severe phototoxic reaction in a patient with idiopathic lung fibrosis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1354-1356.	2.4	20
40	Involvement of Neuro-Immune Interactions in Pruritus With Special Focus on Receptor Expressions. Frontiers in Medicine, 2021, 8, 627985.	2.6	20
41	Highly specific targeting of human acute myeloid leukaemia cells using pharmacologically active nanoconjugates. Nanoscale, 2018, 10, 5827-5833.	5.6	19
42	Allergic contact dermatitis to acid blue 158 in suture material. Contact Dermatitis, 2008, 59, 192-193.	1.4	18
43	The basophil activation test is a helpful diagnostic tool in anaphylaxis to sesame with falseâ€negative specific IgE and negative skin test. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1497-1499.	5.7	17
44	Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severity. Journal of Allergy and Clinical Immunology, 2016, 137, 314-318.e5.	2.9	17
45	Biochemical mechanisms implemented by human acute myeloid leukemia cells to suppress host immune surveillance. Cellular and Molecular Immunology, 2018, 15, 989-991.	10.5	17
46	Contact allergy to dental materials. JDDG - Journal of the German Society of Dermatology, 2012, 10, 391-396.	0.8	14
47	Novel functions of S1P in chronic itchy and inflammatory skin diseases. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 365-372.	2.4	11
48	Neurotrophins in healthy and diseased skin. Giornale Italiano Di Dermatologia E Venereologia, 2010, 145, 205-11.	0.8	11
49	Regulation of melanocortin 1 receptor in allergic rhinitis <i>in vitro</i> and <i>in vivo</i> . Clinical and Experimental Allergy, 2016, 46, 1066-1074.	2.9	9
50	A mild form of dermatomyositis as a prodromal sign of lung adenocarcinoma: a case report. Journal of Medical Case Reports, 2016, 10, 34.	0.8	9
51	Platelet-activating factor decreases skin keratinocyte tight junction barrier integrity. Journal of Allergy and Clinical Immunology, 2016, 138, 1725-1728.e3.	2.9	7
52	The role of basophils in allergic inflammation. Allergo Journal International, 2015, 24, 152-157.	2.0	6
53	Bullous Pemphigoid. New England Journal of Medicine, 2015, 373, 1659-1659.	27.0	6
54	Activation of <scp>KIT</scp> modulates the function of tumor necrosis factorâ€related apoptosisâ€inducing ligand receptor (TRAILâ€R) in mast cells. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 764-774.	5.7	5

Ulrike Raap

#	Article	IF	CITATIONS
55	Intraepidermal neutrophilic dermatosis type of IgA pemphigus with circulating linear IgA disease antibodies associated with ulcerative colitis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e10-e11.	2.4	5
56	Human basophils release the anti-inflammatory cytokine IL-10 following stimulation with α-melanocyte–stimulating hormone. Journal of Allergy and Clinical Immunology, 2021, 147, 1521-1523.e3.	2.9	5
57	Physiology and pathology of eosinophils: Recent developments. Scandinavian Journal of Immunology, 2021, 93, e13032.	2.7	4
58	Rapid therapeutic response of palmoplantar pustulosis under biologic treatment with guselkumab. Dermatologic Therapy, 2021, 34, e14792.	1.7	2
59	Oral Cavity and Allergy: Meeting the Diagnostic and Therapeutic Challenge. Current Oral Health Reports, 2016, 3, 347-355.	1.6	1
60	Diversities of allergic pathologies and their modifiers: Report from the second DGAKI-JSA meeting. Allergology International, 2022, 71, 310-317.	3.3	1
61	Therapeutic Interventions for Itch in AD. Current Treatment Options in Allergy, 2014, 1, 374-383.	2.2	0
62	Localized subepidermalÂblistering: not always bullous pemphigoid but a diagnostic challenge. JDDG - Journal of the German Society of Dermatology, 2018, 16, 205-207.	0.8	0
63	The Complexity of Pruritus Requires a Variety of Treatment Strategies. Current Treatment Options in Allergy, 2019, 6, 189-199.	2.2	0